Skyrizi 360 MG/2.4 ML on-body 2.4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQT5B
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,934
Award facts
- Contract value 100% obligated
- $24,934.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,934 to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body injectors on January 5, 2026. This competitively awarded, firm fixed-price delivery order is scheduled for completion by January 27, 2026, with performance conducted at the contractor's corporate office in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant medication used to treat inflammatory skin conditions such as plaque psoriasis and hidradenitis suppurativa. The order contains no set-aside designation and represents a routine pharmaceutical supply requirement for military and federal healthcare systems.
This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999 and extending through December 2026. As a premier pharmaceutical distributor and critical vendor to the federal healthcare system, AmerisourceBergen Drug Corp supplies a comprehensive range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. The company's demonstrated capability to fulfill complex federal procurement requirements through competitive processes positions it as a significant supplier within the DLA's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQT5B?
SPE2DR26FQT5B was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FQT5B worth?
The government has obligated $24,934 on SPE2DR26FQT5B.
Is contract SPE2DR26FQT5B an order under another contract?
Yes. SPE2DR26FQT5B is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQT5B competed?
The extent of competition for SPE2DR26FQT5B was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award